| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.052 | 0.2 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | itraconazole | CTRPv2 | pan-cancer | AAC | 0.052 | 0.2 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.081 | 0.2 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.2 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |